• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
IDYA

IDYA

IDEAYA Biosciences, Inc.

NASDAQHealthcareBiotechnologyUS

USD28.40

+0.53 (+1.90%)

Rating:C-

Company Profile

CEO

Yujiro S. Hata

IPO Date

2019-05-23

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

Market Metrics

Open

$27.78

Prev. Close

$27.87

Day Low

$27.66

Day High

$28.64

52W Low

$20.45

52W High

$39.28

Market Cap

$2.50B

Volume

1.01M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

31.9%

Avg Negative

1.6%

Avg Neutral

66.4%

News Feed

IDEAYA Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

PRNewsWire·7/12/2021·↑ positive

Ideaya Biosciences Launches Equity Offering Of $80M

Benzinga·7/7/2021·↑ positive

IDEAYA Announces IDE397 Phase 1 Clinical Pharmacodynamic Data and Phase 2 Initiation of Darovasertib and Crizotinib Combination

PRNewsWire
·6/28/2021
·↑ positive

IDEAYA Biosciences to Present at 2021 Jefferies Virtual Healthcare Conference

PRNewsWire·5/24/2021·↑ positive

IDEAYA Biosciences, Inc. (IDYA) Reports Q1 Loss, Misses Revenue Estimates

Zacks Investment Research·5/10/2021·↑ positive

IDEAYA Announces Dose Expansion in Phase 1/2 Study of Darovasertib and Crizotinib Combination based on Early Clinical Efficacy in First Combination Cohort

PRNewsWire·5/10/2021·↑ positive

IDEAYA to Participate in Upcoming May 2021 Investor Relations Event

PRNewsWire·5/6/2021·↑ positive

IDEAYA Biosciences Announces Agenda for Inaugural Synthetic Lethality Investor Day on Tuesday, April 20, 2021

PRNewsWire·4/19/2021·↑ positive

IDEAYA Reports Darovasertib (IDE196) Monotherapy Overall Survival Data and Observes Early Partial Responses in Binimetinib Combination in Metastatic Uveal Melanoma

PRNewsWire·4/16/2021·↑ positive

IDEAYA Announces Investor Day Webcast to Review Clinical Data from Phase 1/2 Trial of Darovasertib (IDE196) Monotherapy and Combination with Binimetinib in Metastatic Uveal Melanoma

PRNewsWire·4/15/2021·↑ positive